Enanta Pharmaceuticals Inc.
ENTA | NASDAQ
$12.29
+$0.18 (+1.49%)
Sep 22, 2026, 12:43 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Sep 29, 2025 | FY 2024 Sep 29, 2024 | FY 2023 Sep 29, 2023 | FY 2022 Sep 29, 2022 | FY 2021 Sep 29, 2021 | FY 2020 Sep 29, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -3.12 | -1.89 | -1.75 | -8.78 | -14.49 | -25.29 |
PEG Ratio | 0.10 | 0.13 | -0.22 | -0.17 | -0.12 | 0.14 |
PS Ratio | 3.91 | 3.24 | 2.96 | 12.40 | 11.80 | 7.45 |
PB Ratio | 3.95 | 1.70 | 1.08 | 3.33 | 2.87 | 2 |
P/FCF Ratio | -7.94 | -2.27 | -2.09 | -12.30 | -16.20 | 161.77 |
P/OCF Ratio | -13.25 | -2.78 | -2.27 | -12.61 | -16.37 | 128.79 |
OCF/S Ratio | -29.50 | -116.45 | -130.24 | -98.40 | -72.11 | 5.79 |
Debt / Equity Ratio | 3.11 | 1.75 | 0.12 | 0.08 | 0.02 | 0.02 |
Quick Ratio | 4.21 | 5.21 | 6.73 | 10.45 | 8.82 | 18.08 |
Current Ratio | 4.21 | 5.21 | 6.73 | 10.45 | 8.82 | 18.08 |
Asset Turnover | 0.23 | 0.18 | 0.17 | 0.23 | 0.22 | 0.25 |
Interest Coverage | -11.11 | -11.12 | -26.65 | n/a | n/a | n/a |
Return on Equity | -126.53% | -90.09% | -61.74% | -37.89% | -19.78% | -7.94% |
Return on Assets | -29.17% | -30.81% | -28.95% | -31.99% | -17.92% | -7.37% |
Return on Invested Capital | -31.44% | -33.76% | -33.90% | -34.89% | -19.68% | -8.84% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 92.98% | 100% | 100% | 100% | 100% | 100% |
Net Profit Margin | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% |
Pretax Profit Margin | -127.90% | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% |
Operating Profit Margin | -130.65% | -179.92% | -173.23% | -143.74% | -112.88% | -34% |
FCF Margin | -49.24% | -142.99% | -141.67% | -100.87% | -72.88% | 4.61% |
EBITDA Margin | -108.35% | -154.52% | -155.90% | -138.36% | -107.39% | -31.02% |
Add to Watchlist
Select watchlists to add or remove ENTA